---
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/293964680.md"
description: "Gossamer Bio shares are trading higher after a pre‑NDA meeting and FDA minutes outlined a path to a September 2026 NDA filing for seralutinib in PAH. The company also regained global rights to the drug and won shareholder approval for a note exchange and reverse split to bolster its capital structure."
datetime: "2026-07-27T18:16:25.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/293964680.md)
  - [en](https://longbridge.com/en/news/293964680.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/293964680.md)
---

# 

Gossamer Bio shares are trading higher after a pre‑NDA meeting and FDA minutes outlined a path to a September 2026 NDA filing for seralutinib in PAH. The company also regained global rights to the drug and won shareholder approval for a note exchange and reverse split to bolster its capital structure.

### Related Stocks

- [GOSS.US](https://longbridge.com/en/quote/GOSS.US.md)

## Related News & Research

- [Gossamer Bio Restructures Debt, Secures Full Control of Lead Drug Candidate](https://longbridge.com/en/news/293964802.md)
- [Gossamer Bio shareholders approved convertible note exchange proposals at special meeting](https://longbridge.com/en/news/293920719.md)
- [GOSS: NDA for seralutinib in PAH on track for September 2026, with global rights and reduced debt](https://longbridge.com/en/news/293945384.md)
- [MapLight says Phase 2 ZEPHYR trial shows ML-007C-MA cuts PANSS score in schizophrenia](https://longbridge.com/en/news/293920685.md)
- [Fortress Biotech subsidiary Urica says Crystalys closes $130 million Series B financing](https://longbridge.com/en/news/293929289.md)